The distinct emergence of phosphorylated and nonphosphorylated tau biomarkers has been leveraged to create a CSF staging model22, where more advanced stages correlate with higher amyloid and tau-PET uptake and greater cognitive impairment. Here, MAPT is linked to Cognitive impairment.